Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies Aug 30, 2017
Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study Aug 2, 2017
Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China Jul 20, 2017
Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer Jun 26, 2017
A New Audio Interview with James Nathanielsz, Propanc Biopharma Inc.'s Chief Executive Officer, is now at SmallCapVoice.com May 23, 2017
